{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:28:43Z","timestamp":1789198123907,"version":"build-2803163510"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1097\/01.fjc.0000180902.78230.fd","type":"journal-article","created":{"date-parts":[[2005,10,11]],"date-time":"2005-10-11T04:01:46Z","timestamp":1129003306000},"page":"585-593","source":"Crossref","is-referenced-by-count":73,"title":["A Review of the Structural and Functional Features of Olmesartan Medoxomil, An Angiotensin Receptor Blocker"],"prefix":"10.1097","volume":"46","author":[{"given":"David E","family":"Mire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonous N","family":"Silfani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K","family":"Pugsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210208","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3317\/jraas.2003.015","article-title":"Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?","volume":"4","author":"Weber","year":"2003","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"R2-4-20210208","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0735-1097(02)02063-6","article-title":"Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.","volume":"40","author":"Wong","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R3-4-20210208","doi-asserted-by":"crossref","first-page":"334","DOI":"10.4065\/78.3.334","article-title":"Therapeutic role of angiotensin II receptor blockers in the treatment of heart failure.","volume":"78","author":"Manohar","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"R4-4-20210208","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1586\/14779072.1.1.51","article-title":"The role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease.","volume":"1","author":"Norris","year":"2003","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R5-4-20210208","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s11906-003-0089-7","article-title":"How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: according to blood pressure or proteinuria?","volume":"5","author":"Segura","year":"2003","journal-title":"Curr Hypertens Rep"},{"issue":"Suppl 12","key":"R6-4-20210208","first-page":"S273","article-title":"Angiotensin receptor blockers: pharmacology and clinical significance.","volume":"10","author":"Mimran","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"R7-4-20210208","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/01.HYP.35.1.155","article-title":"Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function.","volume":"35","author":"Carey","year":"2000","journal-title":"Hypertension"},{"key":"R8-4-20210208","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0014-2999(95)00401-6","article-title":"Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist.","volume":"285","author":"Mizuno","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"R9-4-20210208","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/j.1875-9114.1996.tb03001.x","article-title":"A new class of antihypertensive therapy: angiotensin II receptor antagonists.","volume":"16","author":"Ellis","year":"1996","journal-title":"Pharmacotherapy"},{"key":"R10-4-20210208","doi-asserted-by":"crossref","first-page":"234","DOI":"10.7326\/0003-4819-117-3-234","article-title":"Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology.","volume":"117","author":"Israili","year":"1992","journal-title":"Ann Intern Med"},{"key":"R11-4-20210208","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/BF01116558","article-title":"Angiotensin as a model for hormone-receptor interactions.","volume":"5","author":"Moore","year":"1985","journal-title":"Biosci Rep"},{"key":"R12-4-20210208","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/BF03259832","article-title":"Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.","volume":"1","author":"DiBianco","year":"1986","journal-title":"Med Toxicol"},{"key":"R13-4-20210208","first-page":"489","article-title":"The history of inhibitors of angiotensin converting enzyme.","volume":"50","author":"Vane","year":"1999","journal-title":"J Physiol Pharmacol"},{"key":"R14-4-20210208","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1096\/fj.03-1398bkt","article-title":"From vipers venom to drug design: treating hypertension.","volume":"18","author":"Patlak","year":"2004","journal-title":"FASEB J"},{"key":"R15-4-20210208","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/0002-9149(82)90348-4","article-title":"Development and design of specific inhibitors of angiotensin-converting enzyme.","volume":"49","author":"Cushman","year":"1982","journal-title":"Am J Cardiol"},{"issue":"Suppl 12","key":"R16-4-20210208","first-page":"S255","article-title":"Historical evolution of angiotensin II receptor blockers: therapeutic advantages.","volume":"10","author":"Gavras","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"R18-4-20210208","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0196-9781(90)90093-K","article-title":"1H-NMR studies of [Sar1]angiotensin II conformation by nuclear Overhauser effect spectroscopy in the rotating frame (ROESY): clustering of the aromatic rings in dimethylsulfoxide.","volume":"11","author":"Matsoukas","year":"1990","journal-title":"Peptides"},{"key":"R19-4-20210208","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0196-9781(90)90094-L","article-title":"1H-NMR studies of sarmesin and [des1]sarmesin conformation in dimethylsulfoxide by nuclear Overhauser effect (NOE) enhancement spectroscopy: folding of the N- and C-terminal domains.","volume":"11","author":"Matsoukas","year":"1990","journal-title":"Peptides"},{"key":"R20-4-20210208","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1021\/jm00167a030","article-title":"Structure-activity relationships for the carboxy-terminus truncated analogues of angiotension II, a new class of angiotensin II antagonists.","volume":"33","author":"Bovy","year":"1990","journal-title":"J Med Chem"},{"key":"R21-4-20210208","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/jmr.300070403","article-title":"Receptor interactions of the position 4 side chains of angiotensin II analogues: importance of aromatic ring quadrupole.","volume":"7","author":"Moore","year":"1994","journal-title":"J Mol Recognit"},{"key":"R22-4-20210208","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/0006-291X(90)90378-Z","article-title":"Sarmesin is a partial agonist of angiotensin-II receptors in rabbit, but not in rat, aortic rings.","volume":"169","author":"Criscione","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"R23-4-20210208","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1046\/j.1432-1327.1998.2510448.x","article-title":"The octapeptide angiotensin II adopts a well-defined structure in a phospholipid environment.","volume":"251","author":"Carpenter","year":"1998","journal-title":"Eur J Biochem"},{"key":"R24-4-20210208","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/0006-291X(87)91586-5","article-title":"Mechanistic consequences of charge transfer systems in serine proteases and angiotensin: semiempirical computations.","volume":"145","author":"Rauk","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"R25-4-20210208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0968-0896(99)00266-7","article-title":"The design and synthesis of a potent angiotensin II cyclic analogue confirms the ring cluster receptor conformation of the hormone angiotensin II.","volume":"8","author":"Matsoukas","year":"2000","journal-title":"Bioorg Med Chem"},{"key":"R29-4-20210208","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1021\/jm00167a007","article-title":"The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives.","volume":"33","author":"Duncia","year":"1990","journal-title":"J Med Chem"},{"key":"R30-4-20210208","doi-asserted-by":"crossref","first-page":"III136","DOI":"10.1161\/01.HYP.18.5_Suppl.III136","article-title":"Angiotensin II receptor antagonists. From discovery to antihypertensive drugs.","volume":"18","author":"Timmermans","year":"1991","journal-title":"Hypertension"},{"key":"R31-4-20210208","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1021\/jm950450f","article-title":"Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.","volume":"39","author":"Yanagisawa","year":"1996","journal-title":"J Med Chem"},{"key":"R32-4-20210208","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1021\/jm0309452","article-title":"Recognition of privileged structures by G-protein coupled receptors.","volume":"47","author":"Bondensgaard","year":"2004","journal-title":"J Med Chem"},{"key":"R33-4-20210208","doi-asserted-by":"crossref","first-page":"14024","DOI":"10.1074\/jbc.270.23.14024","article-title":"Mutagenesis and the molecular modeling of the rat angiotensin II receptor (AT1).","volume":"270","author":"Yamano","year":"1995","journal-title":"J Biol Chem"},{"key":"R34-4-20210208","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1021\/jm00075a014","article-title":"Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates.","volume":"36","author":"Ashton","year":"1993","journal-title":"J Med Chem"},{"key":"R35-4-20210208","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3317\/jraas.2000.044","article-title":"Lys(199) mutation of the human angiotensin type 1 receptor differentially affects the binding of surmountable and insurmountable non-peptide antagonists.","volume":"1","author":"Fierens","year":"2000","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"R36-4-20210208","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1074\/jbc.270.5.2284","article-title":"Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms.","volume":"270","author":"Noda","year":"1995","journal-title":"J Biol Chem"},{"key":"R37-4-20210208","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1021\/jm00083a011","article-title":"New nonpeptide angiotensin II receptor antagonists. 1. Synthesis, biological properties, and structure-activity relationships of 2-alkyl benzimidazole derivatives.","volume":"35","author":"Thomas","year":"1992","journal-title":"J Med Chem"},{"key":"R38-4-20210208","first-page":"1","article-title":"Olmesartan medoxomil, a novel potent angiotensin II blocker.","volume":"55","author":"Koike","year":"2003","journal-title":"Annual Report Sankyo Research Laboratories"},{"issue":"Suppl 1","key":"R39-4-20210208","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00004872-200106001-00004","article-title":"The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction.","volume":"19","author":"Laeis","year":"2001","journal-title":"J Hypertens Suppl"},{"key":"R40-4-20210208","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1016\/S0968-0896(02)00239-0","article-title":"5-Substituted-1H-tetrazoles as carboxylic acid isosteres: medicinal chemistry and synthetic methods.","volume":"10","author":"Herr","year":"2002","journal-title":"Bioorg Med Chem"},{"key":"R41-4-20210208","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.amjhyper.2004.03.317","article-title":"The dose-dependent antihypertensive actions of olmesartan medoxomil, an angiotensin (AT) II receptor blocker.","volume":"17","author":"Pugsley","year":"2004","journal-title":"Am J Hypertens"},{"key":"R42-4-20210208","first-page":"62","article-title":"MOSOL, MOPAC for solid-state physics.","volume":"5","author":"Stewart","year":"1985","journal-title":"Quant Chem Prog Exch"},{"issue":"Suppl F","key":"R43-4-20210208","first-page":"26F","article-title":"Pharmacological properties of angiotensin II receptor antagonists.","volume":"15","author":"Timmermans","year":"1999","journal-title":"Can J Cardiol"},{"key":"R44-4-20210208","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0165-6147(02)02081-3","article-title":"Models and methods for studying insurmountable antagonism.","volume":"23","author":"Vauquelin","year":"2002","journal-title":"Trends Pharmacol Sci"},{"key":"R45-4-20210208","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1385\/CBB:35:1:89","article-title":"How can the differences among AT1-receptor antagonists be explained?","volume":"35","author":"Morsing","year":"2001","journal-title":"Cell Biochem Biophys"},{"key":"R46-4-20210208","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0006-2952(00)00546-3","article-title":"A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists.","volume":"61","author":"Vauquelin","year":"2001","journal-title":"Biochem Pharmacol"},{"issue":"Suppl 1","key":"R47-4-20210208","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00004872-200106001-00002","article-title":"In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist.","volume":"19","author":"Koike","year":"2001","journal-title":"J Hypertens Suppl"},{"key":"R48-4-20210208","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1358\/mf.1998.20.9.487530","article-title":"Discovery of new angiotensin II receptor antagonists. A review of pharmacological studies.","volume":"20","author":"Merlos","year":"1998","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"Suppl 2","key":"R49-4-20210208","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1038\/sj.jhh.1001391","article-title":"The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview.","volume":"16","author":"Brunner","year":"2002","journal-title":"J Hum Hypertens"},{"key":"R50-4-20210208","first-page":"826","article-title":"Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist.","volume":"265","author":"Cazaubon","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"R51-4-20210208","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1476-5381.1993.tb13877.x","article-title":"Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.","volume":"110","author":"Criscione","year":"1993","journal-title":"Br J Pharmacol"},{"key":"R52-4-20210208","first-page":"7","article-title":"Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116.","volume":"5","author":"Nishikawa","year":"1994","journal-title":"Blood Press Suppl"},{"issue":"Suppl 1","key":"R53-4-20210208","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/00004872-200106001-00003","article-title":"Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist.","volume":"19","author":"Brunner","year":"2001","journal-title":"J Hypertens Suppl"},{"key":"R54-4-20210208","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1084\/jem.59.3.347","article-title":"Studies on experimental hypertension: I. The production of persistance elevation of systolic blood pressure by means of renal ischemia.","volume":"59","author":"Goldblatt","year":"1934","journal-title":"J Exp Med"},{"key":"R56-4-20210208","first-page":"170","article-title":"Unraveling the mystery of Goldblatt hypertension.","volume":"13","author":"Navar","year":"1998","journal-title":"News Physiol Sci"},{"key":"R57-4-20210208","first-page":"F131","article-title":"Angiotensin-dependent renal mechanisms in two-kidney, one-clip renal vascular hypertension.","volume":"245","author":"Ploth","year":"1983","journal-title":"Am J Physiol"},{"key":"R58-4-20210208","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1524-6175.2001.01136.x","article-title":"Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.","volume":"3","author":"Oparil","year":"2001","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R59-4-20210208","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00129784-200505010-00006","article-title":"Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.","volume":"5","author":"Smith","year":"2005","journal-title":"Am J Cardiovasc Drugs"}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003453-200043050-00033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:57:39Z","timestamp":1785855459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005344-200511000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.fjc.0000180902.78230.fd","relation":{},"ISSN":["0160-2446"],"issn-type":[{"value":"0160-2446","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}